{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:16:05Z","timestamp":1789049765796,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40263-026-01322-8","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T18:27:10Z","timestamp":1784744830000},"page":"1329-1344","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Locoregional CAR T-Cell Trials for the Treatment of Recurrent Glioblastoma: Implications for Neuro-Oncology Practice"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2889-8305","authenticated-orcid":false,"given":"Manina Maja","family":"Etter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5946-4999","authenticated-orcid":false,"given":"Kevin","family":"Akeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-0581","authenticated-orcid":false,"given":"Raphael","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1971-5095","authenticated-orcid":false,"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7570-3902","authenticated-orcid":false,"given":"Gregor","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-3076","authenticated-orcid":false,"given":"Michael","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"10","key":"1322_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"issue":"399","key":"1322_CR2","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O'Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1322_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00233-9","volume":"5","author":"M Prapa","year":"2021","unstructured":"Prapa M, Chiavelli C, Golinelli G, Grisendi G, Bestagno M, Di Tinco R, et al. GD2 CAR T cells against human glioblastoma. NPJ Precis Oncol. 2021;5(1):93. https:\/\/doi.org\/10.1038\/s41698-021-00233-9.","journal-title":"NPJ Precis Oncol"},{"issue":"14","key":"1322_CR4","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2314390.","journal-title":"N Engl J Med"},{"issue":"6","key":"1322_CR5","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.trecan.2024.05.002","volume":"10","author":"P Vaughn-Beaucaire","year":"2024","unstructured":"Vaughn-Beaucaire P, Choi MJ, Liang O, Lawler SE. Intracranial CAR-T cell delivery in glioblastoma patients. Trends Cancer. 2024;10(6):478\u201380. https:\/\/doi.org\/10.1016\/j.trecan.2024.05.002.","journal-title":"Trends Cancer"},{"issue":"3","key":"1322_CR6","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea SD, et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med. 2025;31(3):861\u20138. https:\/\/doi.org\/10.1038\/s41591-024-03451-3.","journal-title":"Nat Med"},{"issue":"16_Suppl.","key":"1322_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1200\/JCO.2025.43.16_suppl.2018","volume":"43","author":"G Li","year":"2025","unstructured":"Li G, Stocksdale BR, Song K-W, Mahdi J, Tanner K, Bertrand S, et al. A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma. J Clin Oncol. 2025;43(16_Suppl.):2018. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.2018.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1322_CR8","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, Wang D, et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30(4):1001\u201312. https:\/\/doi.org\/10.1038\/s41591-024-02875-1.","journal-title":"Nat Med"},{"issue":"5","key":"1322_CR9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results. Nat Med. 2024;30(5):1320\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02893-z.","journal-title":"Nat Med"},{"issue":"3","key":"1322_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, Nasrallah MP, et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer. 2024;5(3):517\u201331. https:\/\/doi.org\/10.1038\/s43018-023-00709-6.","journal-title":"Nat Cancer"},{"issue":"1","key":"1322_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01544-7","volume":"17","author":"H Lin","year":"2024","unstructured":"Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol. 2024;17(1):31. https:\/\/doi.org\/10.1186\/s13045-024-01544-7.","journal-title":"J Hematol Oncol"},{"key":"1322_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1596499","volume":"16","author":"S Yaacoub","year":"2025","unstructured":"Yaacoub S, Vannoy E, Maslova S, Haffey A, Khorsandi K, Sheybani N, et al. CAR-T cell therapy in brain malignancies: obstacles in the face of cellular trafficking and persistence. Front Immunol. 2025;16:1596499. https:\/\/doi.org\/10.3389\/fimmu.2025.1596499.","journal-title":"Front Immunol"},{"key":"1322_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1206983","volume":"13","author":"L Gatto","year":"2023","unstructured":"Gatto L, Ricciotti I, Tosoni A, Di Nunno V, Bartolini S, Ranieri L, et al. CAR-T cells neurotoxicity from consolidated practice in hematological malignancies to fledgling experience in CNS tumors: fill the gap. Front Oncol. 2023;13:1206983. https:\/\/doi.org\/10.3389\/fonc.2023.1206983.","journal-title":"Front Oncol"},{"issue":"1","key":"1322_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41694-9","volume":"14","author":"I Noorani","year":"2023","unstructured":"Noorani I, de la Rosa J. Breaking barriers for glioblastoma with a path to enhanced drug delivery. Nat Commun. 2023;14(1):5909. https:\/\/doi.org\/10.1038\/s41467-023-41694-9.","journal-title":"Nat Commun"},{"issue":"10","key":"1322_CR15","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41416-018-0258-8","volume":"119","author":"NF Brown","year":"2018","unstructured":"Brown NF, Carter TJ, Ottaviani D, Mulholland P. Harnessing the immune system in glioblastoma. Br J Cancer. 2018;119(10):1171\u201381. https:\/\/doi.org\/10.1038\/s41416-018-0258-8.","journal-title":"Br J Cancer"},{"issue":"6190","key":"1322_CR16","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396\u2013401. https:\/\/doi.org\/10.1126\/science.1254257.","journal-title":"Science"},{"issue":"1","key":"1322_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00753-0","volume":"8","author":"S Park","year":"2024","unstructured":"Park S, Maus MV, Choi BD. CAR-T cell therapy for the treatment of adult high-grade gliomas. Precis Oncol. 2024;8(1):279. https:\/\/doi.org\/10.1038\/s41698-024-00753-0.","journal-title":"Precis Oncol"},{"issue":"7","key":"1322_CR18","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/jnnp-2024-333924","volume":"96","author":"FW Vonberg","year":"2025","unstructured":"Vonberg FW, Malik I, O\u2019Reilly M, Hyare H, Carr AS, Roddie C. Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy. J Neurol Neurosurg Psychiatry. 2025;96(7):665\u201378. https:\/\/doi.org\/10.1136\/jnnp-2024-333924.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"1322_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1322_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01712-8","volume":"22","author":"Z Huang","year":"2023","unstructured":"Huang Z, Dewanjee S, Chakraborty P, Jha NK, Dey A, Gangopadhyay M, et al. CAR T cells: engineered immune cells to treat brain cancers and beyond. Mol Cancer. 2023;22(1):22. https:\/\/doi.org\/10.1186\/s12943-022-01712-8.","journal-title":"Mol Cancer"},{"key":"1322_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016208","volume":"13","author":"D Espie","year":"2022","unstructured":"Espie D, Donnadieu E. New insights into CAR T cell-mediated killing of tumor cells. Front Immunol. 2022;13:1016208. https:\/\/doi.org\/10.3389\/fimmu.2022.1016208.","journal-title":"Front Immunol"},{"issue":"2","key":"1322_CR22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20230903","volume":"221","author":"M Ayala Ceja","year":"2024","unstructured":"Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: major process parameters and next-generation strategies. J Exp Med. 2024;221(2):e20230903. https:\/\/doi.org\/10.1084\/jem.20230903.","journal-title":"J Exp Med"},{"key":"1322_CR23","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncolytics. 2016;3:1605. https:\/\/doi.org\/10.1038\/mto.2016.15.","journal-title":"Mol Ther Oncolytics."},{"issue":"7","key":"1322_CR24","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1158\/1078-0432.Ccr-18-1625","volume":"25","author":"BD Choi","year":"2019","unstructured":"Choi BD, Maus MV, June CH, Sampson JH. Immunotherapy for glioblastoma: adoptive T-cell strategies. Clin Cancer Res. 2019;25(7):2042\u20138. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-1625.","journal-title":"Clin Cancer Res"},{"key":"1322_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.817296","volume":"13","author":"YJ Lin","year":"2022","unstructured":"Lin YJ, Mashouf LA, Lim M. CAR T cell therapy in primary brain tumors: current investigations and the future. Front Immunol. 2022;13:817296. https:\/\/doi.org\/10.3389\/fimmu.2022.817296.","journal-title":"Front Immunol"},{"key":"1322_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.851877","volume":"12","author":"JK Jang","year":"2022","unstructured":"Jang JK, Pyo J, Suh CH, Park HS, Chae YK, Kim KW. Safety and efficacy of chimeric antigen receptor T-cell therapy for glioblastoma: a systemic review and meta-analysis. Front Oncol. 2022;12:851877. https:\/\/doi.org\/10.3389\/fonc.2022.851877.","journal-title":"Front Oncol"},{"issue":"1","key":"1322_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.Cd-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 2023;13(1):114\u201331. https:\/\/doi.org\/10.1158\/2159-8290.Cd-22-0750.","journal-title":"Cancer Discov"},{"issue":"8","key":"1322_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102302","volume":"6","author":"ME Barish","year":"2025","unstructured":"Barish ME, Aftabizadeh M, Hibbard J, Blanchard MS, Ostberg JR, Wagner JR, et al. Chlorotoxin-directed CAR T cell therapy for recurrent glioblastoma: interim clinical experience demonstrating feasibility and safety. Cell Rep Med. 2025;6(8):102302. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102302.","journal-title":"Cell Rep Med"},{"issue":"1","key":"1322_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03315-3","volume":"24","author":"T Chen","year":"2024","unstructured":"Chen T, Wang M, Chen Y, Liu Y. Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors. Cancer Cell Int. 2024;24(1):133. https:\/\/doi.org\/10.1186\/s12935-024-03315-3.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"1322_CR30","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28(11):2320\u201339. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.015.","journal-title":"Mol Ther"},{"issue":"1","key":"1322_CR31","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41698-025-01079-1","volume":"9","author":"AC Fern\u00e1ndez-Rilo","year":"2025","unstructured":"Fern\u00e1ndez-Rilo AC, de Billy E, Del Baldo G, De Angelis B, Rossi S, Del Bufalo F, et al. GD2: hopes and challenges for the treatment of pediatric patients with tumors of the central nervous system. Precis Oncol. 2025;9(1):295. https:\/\/doi.org\/10.1038\/s41698-025-01079-1.","journal-title":"Precis Oncol"},{"issue":"22","key":"1322_CR32","doi-asserted-by":"publisher","first-page":"6846","DOI":"10.1158\/1078-0432.Ccr-17-0890","volume":"23","author":"J Felsberg","year":"2017","unstructured":"Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, et al. Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res. 2017;23(22):6846\u201355. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-17-0890.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1322_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01751-9","volume":"22","author":"AA Getu","year":"2023","unstructured":"Getu AA, Tigabu A, Zhou M, Lu J, Fodstad \u00d8, Tan M. New frontiers in immune checkpoint B7-H3 (CD276) research and drug development. Mol Cancer. 2023;22(1):43. https:\/\/doi.org\/10.1186\/s12943-023-01751-9.","journal-title":"Mol Cancer"},{"issue":"4","key":"1322_CR34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K, Roddie C, Scott BJ, Davidson TB, et al. Tumor inflammation-associated neurotoxicity. Nat Med. 2023;29(4):803\u201310. https:\/\/doi.org\/10.1038\/s41591-023-02276-w.","journal-title":"Nat Med"},{"issue":"4","key":"1322_CR35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"1322_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41591-018-0068-9","volume":"24","author":"C Rooney","year":"2018","unstructured":"Rooney C, Sauer T. Modeling cytokine release syndrome. Nat Med. 2018;24(6):705\u20136. https:\/\/doi.org\/10.1038\/s41591-018-0068-9.","journal-title":"Nat Med"},{"issue":"5","key":"1322_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453\u201361. https:\/\/doi.org\/10.1016\/S1470-2045(08)70125-6.","journal-title":"Lancet Oncol"},{"issue":"15","key":"1322_CR38","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/s1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16(15):e534\u201342. https:\/\/doi.org\/10.1016\/s1470-2045(15)00088-1.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1322_CR39","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41577-021-00508-z","volume":"21","author":"AF Salvador","year":"2021","unstructured":"Salvador AF, de Lima KA, Kipnis J. Neuromodulation by the immune system: a focus on cytokines. Nat Rev Immunol. 2021;21(8):526\u201341. https:\/\/doi.org\/10.1038\/s41577-021-00508-z.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"1322_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"1322_CR41","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330. https:\/\/doi.org\/10.1182\/blood-2016-04-703751.","journal-title":"Blood"},{"issue":"5","key":"1322_CR42","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/JCMA.0000000000000302","volume":"83","author":"CJ Chou","year":"2020","unstructured":"Chou CJ, Lin CF, Chen YW, Huang PI, Yang YP, Wang ML, et al. The update of chimeric antigen receptor-T cells therapy in glioblastoma. J Chin Med Assoc. 2020;83(5):442\u20135. https:\/\/doi.org\/10.1097\/JCMA.0000000000000302.","journal-title":"J Chin Med Assoc"},{"issue":"1","key":"1322_CR43","doi-asserted-by":"publisher","DOI":"10.1259\/bjro.20200009","volume":"2","author":"G Abdalla","year":"2020","unstructured":"Abdalla G, Hammam A, Anjari M, D\u2019Arco DF, Bisdas DS. Glioma surveillance imaging: current strategies, shortcomings, challenges and outlook. BJR Open. 2020;2(1):20200009. https:\/\/doi.org\/10.1259\/bjro.20200009.","journal-title":"BJR Open"},{"issue":"27","key":"1322_CR44","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","volume":"42","author":"D Eisenbarth","year":"2023","unstructured":"Eisenbarth D, Wang YA. Glioblastoma heterogeneity at single cell resolution. Oncogene. 2023;42(27):2155\u201365. https:\/\/doi.org\/10.1038\/s41388-023-02738-y.","journal-title":"Oncogene"},{"issue":"10","key":"1322_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012308","volume":"13","author":"CM Walton","year":"2025","unstructured":"Walton CM, Bell M, O\u2019Neil R, Sahin O, Choi BD, Fecci PE, et al. Chimeric antigen receptor (CAR) T-cell therapy for glioblastoma (GBM): current clinical insights, challenges, and future directions. J Immunother Cancer. 2025;13(10):e012308. https:\/\/doi.org\/10.1136\/jitc-2025-012308.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1322_CR46","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac185","volume":"5","author":"A Schmidts","year":"2023","unstructured":"Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, Cahill DP, et al. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma. Neurooncol Adv. 2023;5(1):vdac185. https:\/\/doi.org\/10.1093\/noajnl\/vdac185.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"1322_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54129-w","volume":"15","author":"TA Martins","year":"2024","unstructured":"Martins TA, Kaymak D, Tatari N, Gerster F, Hogan S, Ritz MF, et al. Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRP\u03b3-derived CD47 blocker. Nat Commun. 2024;15(1):9718. https:\/\/doi.org\/10.1038\/s41467-024-54129-w.","journal-title":"Nat Commun"},{"issue":"10","key":"1322_CR48","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1093\/neuonc\/noae126","volume":"26","author":"AJ Hou","year":"2024","unstructured":"Hou AJ, Shih RM, Uy BR, Shafer A, Chang ZL, Comin-Anduix B, et al. IL-13R\u03b12\/TGF-\u03b2 bispecific CAR-T cells counter TGF-\u03b2-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Neuro Oncol. 2024;26(10):1850\u201366. https:\/\/doi.org\/10.1093\/neuonc\/noae126.","journal-title":"Neuro Oncol"},{"key":"1322_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.571951","volume":"11","author":"TA Martins","year":"2020","unstructured":"Martins TA, Schmassmann P, Shekarian T, Boulay JL, Ritz MF, Zanganeh S, et al. Microglia-centered combinatorial strategies against glioblastoma. Front Immunol. 2020;11:571951. https:\/\/doi.org\/10.3389\/fimmu.2020.571951.","journal-title":"Front Immunol"},{"issue":"1","key":"1322_CR50","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, et al. Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018;26(1):31\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.002.","journal-title":"Mol Ther"},{"issue":"1","key":"1322_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/2767-9764.Crc-22-0185","volume":"3","author":"R Starr","year":"2023","unstructured":"Starr R, Aguilar B, Gumber D, Maker M, Huard S, Wang D, et al. Inclusion of 4-1BB costimulation enhances selectivity and functionality of IL13R\u03b12-targeted chimeric antigen receptor T cells. Cancer Res Commun. 2023;3(1):66\u201379. https:\/\/doi.org\/10.1158\/2767-9764.Crc-22-0185.","journal-title":"Cancer Res Commun"},{"issue":"1","key":"1322_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68112-6","volume":"17","author":"X Li","year":"2026","unstructured":"Li X, Shang X, Liu J, Zhang Y, Jia X, Li H, et al. Intrathecal CRISPR-edited allogeneic IL-13R\u03b12 CAR T cells for recurrent high-grade glioma: preclinical characterization and phase I trial. Nat Commun. 2026;17(1):1362. https:\/\/doi.org\/10.1038\/s41467-025-68112-6.","journal-title":"Nat Commun"},{"issue":"8","key":"1322_CR53","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-478255","volume":"122","author":"H Torikai","year":"2013","unstructured":"Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood. 2013;122(8):1341\u20139. https:\/\/doi.org\/10.1182\/blood-2013-03-478255.","journal-title":"Blood"},{"issue":"3","key":"1322_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-014450","volume":"14","author":"CK Ramsoomair","year":"2026","unstructured":"Ramsoomair CK, Daftari M, Benchouia R, Estevez-Ordonez D, Aka A, Himic V, et al. Locoregional delivery of CAR T cells in high-grade gliomas: a systematic analysis of safety, efficacy, and emerging biomarkers of response. J Immunother Cancer. 2026;14(3):e014450. https:\/\/doi.org\/10.1136\/jitc-2025-014450.","journal-title":"J Immunother Cancer"},{"key":"1322_CR55","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","volume":"11","author":"Y Yin","year":"2018","unstructured":"Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, et al. Checkpoint blockade reverses energy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics. 2018;11:20\u201338. https:\/\/doi.org\/10.1016\/j.omto.2018.08.002.","journal-title":"Mol Ther Oncolytics"},{"issue":"26","key":"1322_CR56","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn9440","volume":"8","author":"T Shekarian","year":"2022","unstructured":"Shekarian T, Zinner CP, Bartoszek EM, Duchemin W, Wachnowicz AT, Hogan S, et al. Immunotherapy of glioblastoma explants induces interferon-\u03b3 responses and spatial immune cell rearrangements in tumor center, but not periphery. Sci Adv. 2022;8(26):eabn9440. https:\/\/doi.org\/10.1126\/sciadv.abn9440.","journal-title":"Sci Adv"},{"issue":"13","key":"1322_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cells13131075","volume":"13","author":"D Akhavan","year":"2024","unstructured":"Akhavan D, Subham S, Jeppson JD, Aguilar B, Wong RA, Hibbard JC, et al. Evaluation of the immunomodulatory effects of radiation for chimeric antigen receptor T cell therapy in glioblastoma multiforme. Cells. 2024;13(13):1075. https:\/\/doi.org\/10.3390\/cells13131075.","journal-title":"Cells"},{"issue":"4","key":"1322_CR58","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.Can-17-1788","volume":"78","author":"T Weiss","year":"2018","unstructured":"Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-based CAR T cells and radiotherapy exert synergistic efficacy in glioblastoma. Cancer Res. 2018;78(4):1031\u201343. https:\/\/doi.org\/10.1158\/0008-5472.Can-17-1788.","journal-title":"Cancer Res"},{"key":"1322_CR59","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.3390\/cells13131075","volume":"13","author":"D Akhavan","year":"2024","unstructured":"Akhavan D, Subham S, Jeppson J, Aguilar B, Wong R, Hibbard J, et al. Evaluation of the immunomodulatory effects of radiation for chimeric antigen receptor T cell therapy in glioblastoma multiforme. Cells. 2024;13:1075. https:\/\/doi.org\/10.3390\/cells13131075.","journal-title":"Cells"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01322-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01322-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01322-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:59:52Z","timestamp":1789048792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01322-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1322"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01322-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Manina Maja Etter, Kevin Akeret, Raphael Guzman, Luigi Mariani, Gregor Hutter, and Michael Lim have no conflicts of interest that are directly relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors listed below contributed sufficiently to the project to be included as authors, and all those who are qualified to be authors are listed in the author byline. To the best of our knowledge, we adhered to institutional and international ethical standards. The contributions are as follows: conception and design: MME, KA, LM, RG, GH, ML. Drafting the article: MME, KA. Critically revising the article: all authors. Approved the final version of the manuscript on behalf of all authors: MME. Administrative\/technical\/material support: all authors.","order":7,"name":"Ethics","label":"Authors\u2019 contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}